Business
Oxford Nanopore and A.D.A.M. Innovations Announce International Collaboration to Accelerate Advanced Genomic Medicine in Japan
OXFORD, England & TOKYO, March 17, 2026--Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, and A.D.A.M. Innovations (Japanese corporate name Genesis Healthcare Co.), one of Japan’s leading genetic testing companies, today announce an international collaboration to develop and deploy advanced genomic sequencing and medicine applications based on comprehensive, nanopore sequencing in Japan.
About this update from Oxford Nanopore Technologies Plc
[{"type":"image","alt":"From left to right: Dr. Iri Sato Baran, Genesis Healthcare (A.D.A.M Innovations), Vice Chair of the Board Ambassador Julia Longbottom, British Embassy Foreign, Commonwealth and Development Office Michel Mommejat, Genesis Healthcare (A.D.A.M Innovations), CEO and Executive Director Gretchen Weightman, Oxford Nanopore Technologies, Senior Vice President Commercial and General Manager APAC, Dr. Toshiharu Furukawa, LDP, Chair of Medical Information Policy and Genomic Medicine, House of Councillors, Hirokazu Shimoda, Japan Agency for Medical Research and Development, Senior Director","displaySize":"","headline":null,"caption":"From left to right: Dr. Iri Sato Baran, Genesis Healthcare (A.D.A.M Innovations), Vice Chair of the Board Ambassador Julia Longbottom, British Embassy Foreign, Commonwealth and Development Office Michel Mommejat, Genesis Healthcare (A.D.A.M Innovations), CEO and Executive Director Gretchen Weightman, Oxford Nanopore Technologies, Senior Vice President Commercial and General Manager APAC, Dr. Toshiharu Furukawa, LDP, Chair of Medical Information Policy and Genomic Medicine, House of Councillors, Hirokazu Shimoda, Japan Agency for Medical Research and Development, Senior Director","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":389,"url":"https://media.zenfs.com/en/business-wire.com/0c1da623f6eab63a8cf56d8c076e17e0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jFphOEVdPGktIBAIN2S3EQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTc3ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0c1da623f6eab63a8cf56d8c076e17e0","width":480,"height":389}},"lazy":false},{"type":"text","content":"OXFORD, England & TOKYO, March 17, 2026--(BUSINESS WIRE)--Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, and A.D.A.M. Innovations (Japanese corporate name Genesis Healthcare Co.), one of Japan’s leading genetic testing companies, today announce an international collaboration to develop and deploy advanced genomic sequencing and medicine applications based on comprehensive, nanopore sequencing in Japan.","length":484,"tagName":"p"},{"type":"text","content":"In its initial phase, the collaboration has the potential to establish Oxford Nanopore’s information-rich, real-time sequencing technology across A.D.A.M. I...